Skip to content

Analysis of the therapeutic effect of personalized vestibular rehabilitation training in the treatment of atypical BPPV

Analysis of the therapeutic effect of personalized vestibular rehabilitation training in the treatment of atypical BPPV

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076670
Enrollment
Unknown
Registered
2023-10-16
Start date
2023-10-16
Completion date
Unknown
Last updated
2023-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atypical BPPV

Interventions

Otolith reduction group:Earstone reduction+sibirin
Vestibular rehabilitation group:Vestibular rehabilitation+Sibeline

Sponsors

The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: a. Sign an informed consent form; b. Age range from 18 to 75 years old; c. Conforming to atypical BPPV: (1) The main complaint is temporary dizziness during the past month of lying up and turning over in bed, which persists for more than one week without relief; (2) The displacement test (Dix hallpike test and Roll test) can induce dizziness but no nystagmus is observed; (3) The displacement test induced nystagmus but no dizziness; ? The displacement experiment did not induce typical nystagmus

Exclusion criteria

Exclusion criteria: Exclusion criteria: a. Bilateral hearing is significantly asymmetrical; b. Severe cervical spondylosis; c. Motor, visual, and cognitive impairments; d. History of migraine; e. Severe cardiovascular and cerebrovascular diseases, such as carotid artery stenosis; f. Pregnancy/breastfeeding or planned pregnancy during the study period; g. Take vestibular inhibitors, antihistamines, and/or ototoxic drugs in the first 3 months; h. Atypical BPPV with non otolith impaction and otolith diversion; i. Central nervous system lesions; f. Merge with other diseases

Design outcomes

Primary

MeasureTime frame
VAS, ABC, DHI scales;

Secondary

MeasureTime frame
Total effective rate;VNG;vHIT;VEMP;duration of symptoms;Recurrence rate;Overall efficacy evaluation indicators;

Countries

China

Contacts

Public ContactLintao Gu

The First Affiliated Hospital of Shandong First Medical University

glt_2010@126.com+86 185 5310 4640

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026